U.S. Markets closed
  • S&P 500

    3,901.36
    +0.57 (+0.01%)
     
  • Dow 30

    31,261.90
    +8.77 (+0.03%)
     
  • Nasdaq

    11,354.62
    -33.88 (-0.30%)
     
  • Russell 2000

    1,773.27
    -2.96 (-0.17%)
     
  • Crude Oil

    110.35
    +0.46 (+0.42%)
     
  • Gold

    1,845.10
    +3.90 (+0.21%)
     
  • Silver

    21.87
    -0.03 (-0.13%)
     
  • EUR/USD

    1.0562
    -0.0026 (-0.2429%)
     
  • 10-Yr Bond

    2.7870
    -0.0680 (-2.38%)
     
  • Vix

    29.43
    +0.08 (+0.27%)
     
  • GBP/USD

    1.2495
    +0.0020 (+0.1587%)
     
  • USD/JPY

    127.8500
    +0.0560 (+0.0438%)
     
  • BTC-USD

    29,384.41
    +168.87 (+0.58%)
     
  • CMC Crypto 200

    650.34
    -23.03 (-3.42%)
     
  • FTSE 100

    7,389.98
    +87.24 (+1.19%)
     
  • Nikkei 225

    26,739.03
    +336.19 (+1.27%)
     

Is Gilead (GILD) A Smart Long-Term Investment?

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Miller Howard Investments, an investment management firm, published its third-quarter 2021 investor letter – a copy of which can be downloaded here. A quarterly return of 3.5% (yield) was recorded by the fund for the third quarter of 2021, compared to the 1.5% for the S&P 500 for the same period. You can take a look at the fund’s top 5 holdings to have an idea about their best picks for 2021.

Miller Howard Investments, in its Q3 2021 investor letter, mentioned Gilead Sciences, Inc. (NASDAQ: GILD) and discussed its stance on the firm. Gilead Sciences, Inc. is a Foster City, California-based biotechnology company with a $91.5 billion market capitalization. GILD delivered a 25.25% return since the beginning of the year, while its 12-month returns are up by 28.40%. The stock closed at $72.97 per share on December 29, 2021.

Here is what Miller Howard Investments has to say about Gilead Sciences, Inc. in its Q3 2021 investor letter:

"While optimistic about a recovery, we continue to balance our cyclical holdings with dividend-payers in stable, less economically-sensitive industries. We hold three pharmaceutical companies, (which includes) Gilead (GILD). All three have strong cash flows and balance sheets, making their high dividends reasonably safe. The investment controversy surrounding these pharma companies is whether they can develop or acquire new products to replace their current blockbuster drugs. The low valuations on these stocks reflects what we believe to be undue pessimism by investors on the prospects for new drugs."

10 Pharmacist Shortage Countries in Need of Pharmacists in 2017
10 Pharmacist Shortage Countries in Need of Pharmacists in 2017

kurhan / shutterstock.com

Based on our calculations, Gilead Sciences, Inc. (NASDAQ: GILD) was not able to clinch a spot in our list of the 30 Most Popular Stocks Among Hedge Funds. GILD was in 55 hedge fund portfolios at the end of the third quarter of 2021, compared to 54 funds in the previous quarter. Gilead Sciences, Inc. (NASDAQ: GILD) delivered a 4.29% return in the past 3 months.

Earlier this year, we also shared another hedge fund's views on GILD in another article. You can find more than 100 investor letters from hedge funds and prominent investors on our hedge fund investor letters 2021 Q3 page.

Disclosure: None. This article is originally published at Insider Monkey.